8-K: Cardiff Oncology Announces Second Quarter 2024 Results and Provides Business Update

Cardiff Oncology reported its second quarter 2024 financial results, highlighted by a $60 million cash balance and an anticipated data readout for its CRDF-004 trial in the second half of 2024.

Summary

• Cardiff Oncology announced its financial results for the second quarter of 2024, ending June 30th.
• The company had approximately $60.3 million in cash, cash equivalents, and short-term investments as of June 30, 2024.
• Net cash used in operating activities for the second quarter was approximately $9.2 million, an increase from $7.1 million in the same period of 2023.
• Total operating expenses for the quarter were approximately $12.7 million, a slight increase from $12.3 million in the same period of 2023.
• The company anticipates its current cash resources will fund operations through the end of Q3 2025.
• An initial data readout from the first-line RAS-mutated mCRC randomized CRDF-004 trial is expected in the second half of 2024.
• Preclinical data supports onvansertib's ability to overcome resistance to PARP inhibitors in ovarian cancer.
• Five abstracts were presented at AACR, providing a scientific rationale for onvansertib's clinical development.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong cash reserves and upcoming clinical trial data, but also acknowledges the inherent risks of clinical development and the need for potential future financing.

Positives

• The company has a strong cash position of $60.3 million.
• The cash runway is projected to last through the end of Q3 2025.
• The upcoming data readout from the CRDF-004 trial is a significant milestone.
• Preclinical data supports the potential of onvansertib to address PARP inhibitor resistance.
• The company presented five abstracts at AACR, highlighting the scientific rationale for onvansertib.

Negatives

• Net cash used in operating activities increased by $2.1 million compared to the same quarter last year.
• Total operating expenses increased slightly compared to the same quarter last year.

Risks

• Clinical trials are lengthy and expensive with uncertain outcomes.
• Clinical trials may be suspended or discontinued due to unexpected side effects.
• Results of preclinical studies or clinical trials could be unfavorable or delayed.
• The company may need additional financing in the future.
• Business interruptions, such as pandemics or cyber-attacks, could harm the company's financial condition.
• There are uncertainties of government or third-party payer reimbursement.
• The company depends on key personnel.
• There is substantial competition in the biotechnology industry.
• There are uncertainties of patent protection and litigation.
• The company depends on third parties.
• There are risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations.

Future Outlook

The company expects an initial data readout from the first-line RAS-mutated mCRC randomized CRDF-004 trial in the second half of 2024 and believes its current cash resources are sufficient to fund operations through the end of Q3 2025.

Management Comments

• The first half of 2024 has been productive for Cardiff Oncology as we have been focused on the enrollment of our CRDF-004 trial for first-line treatment of RAS-mutated mCRC evaluating onvansertib + chemo/bev, said Mark Erlander, Ph.D., Chief Executive Officer of Cardiff Oncology.
• We are working closely with our clinical operations partner, Pfizer Ignite, and are encouraged by ongoing enrollment trends at the 33 sites currently open to enrollment.
• We believe the robust body of evidence generated to date from our Phase 1b/2 and ONSEMBLE trials lays a strong foundation for our upcoming data readout for CRDF-004 later this year.
• We are optimistic about the potential of onvansertib to change the treatment paradigm for the entire first-line RAS-mutated mCRC patient population who has not had access to any new therapies in over 20 years.

Industry Context

The announcement highlights Cardiff Oncology's progress in developing onvansertib, a PLK1 inhibitor, for various cancers, particularly RAS-mutated mCRC, where there has been a lack of new therapies for over 20 years. The company is also exploring onvansertib's potential in other cancers, such as ovarian and pancreatic cancer, which aligns with the broader industry trend of developing targeted therapies for specific cancer subtypes.

Comparison to Industry Standards

• Cardiff Oncology's focus on PLK1 inhibition is a differentiated approach compared to many other oncology companies.
• The company's cash runway through Q3 2025 is a positive sign, but it is important to compare this to the cash burn rates and timelines of similar clinical-stage biotech companies.
• The planned investigator-initiated trial for mPDAC using NALIRIFOX is a strategic move, aligning with the latest standard of care, and should be compared to other companies' approaches in this area.
• The preclinical data on overcoming PARP inhibitor resistance is promising and should be compared to other companies working on similar resistance mechanisms, such as Clovis Oncology and AstraZeneca.
• The company's clinical trial enrollment progress should be compared to other companies in the same space, such as Mirati Therapeutics and Revolution Medicines, to assess its efficiency.

Stakeholder Impact

• Shareholders will be interested in the upcoming CRDF-004 trial data and the company's cash runway.
• Employees will be impacted by the company's progress and financial stability.
• Patients with RAS-mutated mCRC may benefit from the potential of onvansertib.
• The company's suppliers and partners will be impacted by the company's financial health and clinical trial progress.

Next Steps

• The company will proceed with the planned investigator-initiated trial for mPDAC.
• The company will continue to enroll patients in the CRDF-004 trial.
• The company will announce details of the new mPDAC trial when available.
• The company will provide an initial data readout from the CRDF-004 trial in the second half of 2024.

Key Dates

Keywords

Onvansertib, PLK1 inhibition, RAS-mutated mCRC, Metastatic pancreatic cancer, Ovarian cancer, Clinical trials, Biotechnology, AACR, CRDF-004, PARP inhibitors